Experimental approach for the search of effective drug combination in cancer chemotherapy.
A comparative assay of cytostatic combinations was carried out in a number of transplantable mouse tumors: L1210, Lewis lung carcinoma, Sarcoma 180 and others. The results suggest that the combination cyclophosphamide (CPH) plus procarbazine (PROC) enhances the antitumoral activity in comparison with monochemotherapy. The combination CPH + PROC can be used as basis for the elaboration of more effective polychemotherapy schemes. Combination of CPH + PROC + Prospidine and CPH + PROC + CCNU resulted in enhancement of the treatment effect in experimental tumors.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy; D008130:Lomustine / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D011344:Procarbazine / Q000008:administration & dosage; D011447:Prospidium / Q000008:administration & dosage; D012513:Sarcoma, Experimental / Q000188:drug therapy
D000970:Antineoplastic Agents; D011344:Procarbazine; D008130:Lomustine; D011447:Prospidium; D003520:Cyclophosphamide